NCT05608044Phase 2Active not recruiting

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-09Estimated

Enrollment · participants234Actual

Source updated2025-09-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Metastatic Colorectal Cancer

Treatments or interventions studied

BotensilimabDrugAlso known as AGEN1181
BalstilimabDrugAlso known as AGEN2034
Standard of CareDrug

Primary outcomes · main study measures

measure: Objective Response Rate; description: Objective response rate is defined as the proportion of participants with complete response or partial response, as assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).; timeFrame: First dose through up to 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history